Literature DB >> 2715279

Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation.

S C Szathmary1.   

Abstract

The analytical method described here provides the appropriate sensitivity and selectivity for the determination of unlabelled hydroxypropyl-beta-cyclodextrin as a parenteral carrier in pharmaceutical formulations. The method may also be used in clinical trials evaluating the fate and pharmacokinetic profile of this compound, which was isolated from the biological matrix by solid-phase extraction with Bond Elut C18 cartridges. The lack of uniformity of the product was circumvented by the use of a size-exclusion chromatographic column. An indirect colorimetric complexation method was used for detection. The detection limit was 0.1 micrograms per 2 ml of biological fluid and the extraction recovery was sufficient (78%).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715279     DOI: 10.1016/s0378-4347(00)83011-x

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis.

Authors:  C Schmitt; Y Perel; J L Harousseau; S Lemerle; E Chwetzoff; J P le Moing; J C Levron
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Development and validation of sensitive LC-MS/MS assays for quantification of HP-β-CD in human plasma and CSF.

Authors:  Hui Jiang; Rohini Sidhu; Hideji Fujiwara; Marc De Meulder; Ronald de Vries; Yong Gong; Mark Kao; Forbes D Porter; Nicole M Yanjanin; Nuria Carillo-Carasco; Xin Xu; Elizabeth Ottinger; Myra Woolery; Daniel S Ory; Xuntian Jiang
Journal:  J Lipid Res       Date:  2014-05-27       Impact factor: 5.922

3.  The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat.

Authors:  H W Frijlink; J Visser; N R Hefting; R Oosting; D K Meijer; C F Lerk
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

4.  Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.

Authors:  M A Boogaerts; J Maertens; R Van Der Geest; A Bosly; J M Michaux; A Van Hoof; M Cleeren; R Wostenborghs; K De Beule
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.

Authors:  L de Repentigny; J Ratelle; J M Leclerc; G Cornu; E M Sokal; P Jacqmin; K De Beule
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.

Authors:  John F Mohr; Kevin W Finkel; John H Rex; Jose R Rodriguez; Gerhard J Leitz; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.

Authors:  Susan M Abdel-Rahman; Richard F Jacobs; Joseph Massarella; Ralph E Kauffman; John S Bradley; Hui C Kimko; Gregory L Kearns; Kevin Shalayda; Christopher Curtin; Samuel D Maldonado; Jeffrey L Blumer
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.